Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors With KRAS G12C Mutations”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Early research (Phase 1)Study completedNCT04330664
What this trial is testing

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 86
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Early research (Phase 1)Looking for participantsNCT06447662
What this trial is testing

Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Who this might be right for
Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
Pfizer 330
Early research (Phase 1)Study completedNCT04006301
What this trial is testing

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Who this might be right for
NeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more
Janssen Research & Development, LLC 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06435455
What this trial is testing

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 126
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Active Not RecruitingNCT05194995
What this trial is testing

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced Colorectal CancerSmall Intestinal CancerAppendiceal Cancer
Allist Pharmaceuticals, Inc. 48
Testing effectiveness (Phase 2)Ended earlyNCT04165031
What this trial is testing

LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 5
Early research (Phase 1)UnknownNCT05263986
What this trial is testing

The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumor
Zai Lab (Shanghai) Co., Ltd. 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT05358249
What this trial is testing

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung+8 more
Novartis Pharmaceuticals 74
Early research (Phase 1)Looking for participantsNCT06383871
What this trial is testing

A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

Who this might be right for
Advanced Malignant Tumour
Shandong Suncadia Medicine Co., Ltd. 233
Early research (Phase 1)Active Not RecruitingNCT04973163
What this trial is testing

Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 30
Early research (Phase 1)Looking for participantsNCT07094204
What this trial is testing

Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Who this might be right for
Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Astellas Pharma Inc 364
Testing effectiveness (Phase 2)Active Not RecruitingNCT04956640
What this trial is testing

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Who this might be right for
Carcinoma, Non-Small-Cell LungColorectal NeoplasmsEndometrial Neoplasms+3 more
Eli Lilly and Company 540
Early research (Phase 1)Active Not RecruitingNCT04185883
What this trial is testing

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Who this might be right for
Advanced Solid TumorsKirsten Rat Sarcoma (KRAS) pG12C Mutation
Amgen 610
Testing effectiveness (Phase 2)Study completedNCT05005234
What this trial is testing

GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

Who this might be right for
KRAS G12C
Innovent Biologics (Suzhou) Co. Ltd. 334
Early research (Phase 1)UnknownNCT06006793
What this trial is testing

SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD 50
Load More Results